Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares
Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.
MINYM can be safely used by patients above 9 years of age.
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
Alopecia areata usually presents as a few small bald patches in the head
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
Futnani has over two decades of experience in delivering growth and transformation that spans several therapeutic areas.
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
Multiples is the first private equity (PE) investor in the company
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
Subscribe To Our Newsletter & Stay Updated
